UNSPSC 51441612: Ibritumomab tiuxetan 90y

This classification denotes an immunoconjugate, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 4Q52C550XK. The European Medicines Agency schedules Ibritumomab tiuxetan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20031. Ibritumomab tiuxetan generally arises in the molecular formula C23H32N5O10S. The term IBRITUMOMAB TIUXETAN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 14, no. 1, 2000, list 43.) SMILES: none.

UNSPSC 51441612 Ibritumomab tiuxetan 90y is a Commodity code nominally designating a radiopharmaceutical product, but recent state and local procurement activity shows little alignment with this specific pharmaceutical agent. The opportunities posted under this code span radiologic equipment procurement, X-ray system maintenance and warranty services, and unrelated chemical supplies (copper sulfate), indicating either systematic miscoding or incidental tagging that does not reflect the code's intended scope. The issuing bodies are county-level jurisdictions — Maricopa County in Arizona, Escambia County in Florida, Broward County in Florida, and Pasco County in Florida — purchasing through standard competitive vehicles including IFBs, sole-source notices, RFIs, and RFQs. None of the recent opportunities actually solicit ibritumomab tiuxetan or radiopharmaceutical products of any kind.

The geographic concentration visible in recent postings is heavily weighted toward Florida counties, with one Arizona posting. Maricopa County (Arizona) issued an IFB (362910) on October 1, 2026, for radiologic equipment and installation services at three colleges, with proposals due October 22, 2026. Escambia County Correction (Florida) posted a sole-source procurement notice (SSCORALM2526005) on August 12, 2026, for extended warranty coverage on specified X-ray machines, responses due August 19, 2026. Broward County Aviation Department (Florida) issued an RFI (BLD2132311F1) on June 25, 2026, to challenge or confirm sole-source designation for Rapiscan X-ray system maintenance services, closing July 28, 2026. The code does not show robust recent activity aligned with its pharmaceutical classification and warrants review for potential recoding or filtering in portfolio targeting.